@article{Neetha_Panicker_Sidharthan_2015, title={IMMEDIATE ADVERSE DRUG EVENTS WITH RITUXIMAB THERAPY IN NON-MALIGNANT HEMATOLOGICAL DISORDERS}, volume={8}, url={https://journals.innovareacademics.in/index.php/ajpcr/article/view/5813}, abstractNote={<p>Objective: Rituximab therapy has become a promising therapeutic option for various non-malignant hematological disorders, after being reported<br />by many case reports. The objective of this study was to evaluate the immediate, infusion-related adverse drug events (ADE) of patients who received<br />rituximab for non-malignant, hematological disorders, in a tertiary healthcare center in India. <br />Methods: 14 patients (6 with primary immune thrombocytopenia, 4 with autoimmune hemolytic anemia, 3 with thrombotic thrombocytopenic<br />purpura, 1 with acquired hemophilia) were enrolled in the study. Patients were assessable for immediate infusion-related toxicity noted predominately<br />within 5 hrs of administration of rituximab infusion. <br />Results: Rituximab therapy was tolerated without major ADE. None of the patients experienced high-grade adverse events. The population who<br />experienced ADE (Grades 1-2) frequently had toxicities that suspected to result from infusion-related cytokine release syndrome (IRCRS) and<br />sometimes required cessation of the infusion and supportive intervention. Patients were monitored for 20 types of ADEs associated with IRCRS.<br />11 types of; mild to moderate (Grades 1 and 2) toxicities resulting from IRCRS were experienced by patients. Mean patients who experienced IRCRS<br />was 1.95 (13.93%), whereas majority of the study population tolerated therapy without IRCRS (86.78%). Among other toxicities, Grade 2 urinary tract<br />infection (UTI) (n=2, 14.29%); Grade 2 hyperglycemia (n=1, 7.14%) and Grade 1 myalgia (n=1, 7.14%) were observed. <br />Conclusion: Toxicity profile of patients with non-malignant hematological disorders shows that rituximab is a safer biological therapy.<br />Keywords: Rituximab, Infusion related cytokine release syndrome, Adverse drug events, Immediate toxicities, Benign, Non-malignant, Hematological<br />disorders.</p>}, number={5}, journal={Asian Journal of Pharmaceutical and Clinical Research}, author={Neetha, Alice and Panicker, Naveen Kumar and Sidharthan, Neeraj}, year={2015}, month={Sep.}, pages={71–72} }